LMT:CA:CDX-Luminor Medical Technologies Inc

EQUITY | Medical Diagnostics & Research | TSX Venture Exchange

Last Closing

USD 0.35

Change

0.00 (0.00)%

Market Cap

USD 6.09M

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Luminor Medical Technologies Inc is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing LMT:CA

HAZ 0.00 % 1.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 900.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 900.00% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7,843.72% N/A N/A N/A N/A
Dividend Return 7,843.72% N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15,374.11% N/A N/A N/A N/A
Risk Adjusted Return 51.02% N/A N/A N/A N/A
Market Capitalization 6.09M N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -1.09 N/A N/A
Price/Book Ratio -1.06 N/A N/A
Price / Cash Flow Ratio -0.43 N/A N/A
Price/Free Cash Flow Ratio -1.21 N/A N/A
Management Effectiveness  
Return on Equity 54.73% N/A N/A
Return on Invested Capital 78.67% N/A N/A
Return on Assets -282.21% N/A N/A
Debt to Equity Ratio -55.75% N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Negative Book Value

The company has negative book value.